findmyKOL
Clinical trialNCT05068427CompletedPhase 2Interventional

Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC.

SponsorChipscreen Biosciences, Ltd.Enrollment34Non Small Cell Lung Cancer
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

12 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

China
  • the Second Hospital of Anhui Medical University

    Hefei, Anhui, China

  • Southern Medical University Affiliated Nanfang Hospital

    Guangzhou, Guangdong, China

  • Sun Yat-Sen University Cancer Center

    Guangzhou, Guangdong, China

  • Guangxi Medical University Affiliated Tumor Hospital

    Nanning, Guangxi, China

  • Baoding No.2 Central Hospital

    Baoding, Hebei, China

  • Henan Cancer Center

    Zhengzhou, Henan, China

  • Nantong Tumor Hospital

    Nantong, Jiangsu, China

  • Xuzhou Central Hospital

    Xuzhou, Jiangsu, China

  • Linyi Cancer Hospital

    Linyi, Shandong, China

  • Shanghai Chest Hospital

    Shanghai, Shanghai Municipality, China

  • Shanghai East Hospital

    Shanghai, Shanghai Municipality, China

  • Zhejiang Provincial People'S Hospital

    Hangzhou, Zhejiang, China

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
23 Nov 2021
Primary completion
23 Feb 2023
Completion
16 May 2024
Last update posted
7 Aug 2024
Registered enrollment
34
Registry id
NCT05068427

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.